

Termination of Coverage

November 19, 2019

Jason H. Kolbert
Director of Research
646-465-6891

Research Prioritization

Effective immediately, Dawson James Securities, Inc. has terminated research coverage of the following companies as a result of a reprioritizing of resources responsible for coverage. The rating and date of the last report are shown adjacent to the closing price of 11/18/2019 in the format (Date of last report/Last rating).

Summary

- Biocept (BIOC); Initiation; 10/3/2018 Buy \$0.55
- Cancer Genetics (CGIX); Company Update 4/6/2018, Neutral \$2.17
- Champions Oncology (CSBR); Company Update 1/14/2019, Buy \$5.36
- Interpace Diagnostics (IDXG); Company Update 10/17/2019, Buy \$0.68
- Mynd Analytics* (EMMA); Company Update 9/24/2019, Neutral \$2.85
- Onconova (ONTX); Company Update 1/18/2018 Buy \$0.34
- Oncosec (ONCS); Company Update 11/7/2019 Neutral \$1.90
- Strata Skin Sciences (SSKN); Initiation 9/4/18 Buy \$2.47

Effective upon this termination of rating, investors should no longer rely on any of our prior research, financial estimates, or ratings for these companies.

* Mynd Analytics changed its ticker to EMMA and is now part of Emmaus.

Important Disclosures:

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

- Biocept (BIOC); Initiation; 10/3/2018 Buy \$0.55
- Cancer Genetics (CGIX); Company Update 4/6/2018, Neutral \$2.17
- Champions Oncology (CSBR); Company Update 1/14/2019, Buy \$5.36
- Interpace Diagnostics (IDXG); Company Update 10/17/2019, Buy \$0.68
- Mynd Analytics* (EMMA); Company Update 9/24/2019, Neutral \$2.85
- Onconova (ONTX); Company Update 1/18/2018 Buy \$0.34
- Oncosec (ONCS); Company Update 11/7/2019 Neutral \$1.90
- Strata Skin Sciences (SSKN); Initiation 9/4/18 Buy \$2.47

The Firm does not make a market in the securities of the subject company(s). The Firm has not engaged in investment banking relationships with these companies in the prior twelve months, as a manager or co-manager of a public offering and has not received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of October 31, 2019, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	23	88%	2	9%
Market Perform (Neutral)	3	12%	0	0%
Market Underperform (Sell)	0	0%	0	0%
Total	26	100%	2	8%

Accurate as of 11.18.19

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.